1835 related articles for article (PubMed ID: 14530780)
1. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.
Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP
Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780
[TBL] [Abstract][Full Text] [Related]
2. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for candidemia-related mortality at a medical center in central Taiwan.
Cheng YR; Lin LC; Young TG; Liu CE; Chen CH; Tsay RW
J Microbiol Immunol Infect; 2006 Apr; 39(2):155-61. PubMed ID: 16604249
[TBL] [Abstract][Full Text] [Related]
4. Species distribution, antifungal susceptibility and clonal relatedness of Candida isolates from patients in neonatal and pediatric intensive care units at a medical center in Turkey.
Kuzucu C; Durmaz R; Otlu B; Aktas E; Gulcan H; Cizmeci Z
New Microbiol; 2008 Jul; 31(3):401-8. PubMed ID: 18843896
[TBL] [Abstract][Full Text] [Related]
5. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999.
Cheng MF; Yu KW; Tang RB; Fan YH; Yang YL; Hsieh KS; Ho M; Lo HJ
Diagn Microbiol Infect Dis; 2004 Jan; 48(1):33-7. PubMed ID: 14761719
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility of yeasts isolated from patients in intensive care units to fluconazole and amphotericin B during a 3-year period.
Kucukates E; Erturan Z; Susever S; Yegenoglu Y
APMIS; 2005 Apr; 113(4):278-83. PubMed ID: 15865609
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibility of oral Candida to seven antifungal agents.
Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
[TBL] [Abstract][Full Text] [Related]
8. Epidemiologic analysis and antifungal susceptibility of Candida blood isolates in southern Taiwan.
Chen TC; Chen YH; Tsai JJ; Peng CF; Lu PL; Chang K; Hsieh HC; Chen TP
J Microbiol Immunol Infect; 2005 Jun; 38(3):200-10. PubMed ID: 15986071
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility of 115 isolates of Candida to amphotericin B, fluconazole and itraconazole.
Mallié M; Bastide JM
Drugs Exp Clin Res; 1996; 22(6):301-7. PubMed ID: 9034756
[TBL] [Abstract][Full Text] [Related]
10. Antifungal susceptibility testing and the correlation with clinical outcome in neonatal candidemia.
Huang YC; Kao HT; Lin TY; Kuo AJ
Am J Perinatol; 2001 May; 18(3):141-6. PubMed ID: 11414524
[TBL] [Abstract][Full Text] [Related]
11. [Neonatal Candida infections and the antifungal susceptibilities of the related Candida species].
Altuncu E; Bilgen H; Cerikçioğlu N; Ilki A; Ulger N; Bakır M; Akman I; Ozek E
Mikrobiyol Bul; 2010 Oct; 44(4):593-603. PubMed ID: 21063972
[TBL] [Abstract][Full Text] [Related]
12. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).
Swinne D; Watelle M; Van der Flaes M; Nolard N
Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).
Leroy O; Gangneux JP; Montravers P; Mira JP; Gouin F; Sollet JP; Carlet J; Reynes J; Rosenheim M; Regnier B; Lortholary O;
Crit Care Med; 2009 May; 37(5):1612-8. PubMed ID: 19325476
[TBL] [Abstract][Full Text] [Related]
14. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
[TBL] [Abstract][Full Text] [Related]
15. Emergence of non-albicans Candida species and antifungal resistance in a tertiary care hospital.
Capoor MR; Nair D; Deb M; Verma PK; Srivastava L; Aggarwal P
Jpn J Infect Dis; 2005 Dec; 58(6):344-8. PubMed ID: 16377864
[TBL] [Abstract][Full Text] [Related]
16. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
17. [Biofilm production and antifungal susceptibility patterns of Candida species].
Yücesoy M; Karaman M
Mikrobiyol Bul; 2004; 38(1-2):91-8. PubMed ID: 15293907
[TBL] [Abstract][Full Text] [Related]
18. Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts.
Park BJ; Park JC; Taguchi H; Fukushima K; Hyon SH; Takatori K
Biochem Biophys Res Commun; 2006 Aug; 347(2):401-5. PubMed ID: 16831406
[TBL] [Abstract][Full Text] [Related]
19. [Multicenter study of fungemia due to yeasts in Argentina].
Rodero L; Davel G; Soria M; Vivot W; Córdoba S; Canteros CE; Saporiti A;
Rev Argent Microbiol; 2005; 37(4):189-95. PubMed ID: 16502638
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
Horn DL; Neofytos D; Anaissie EJ; Fishman JA; Steinbach WJ; Olyaei AJ; Marr KA; Pfaller MA; Chang CH; Webster KM
Clin Infect Dis; 2009 Jun; 48(12):1695-703. PubMed ID: 19441981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
